Exposing Key Features on Familial Chylomicronemia Syndrome

Mini Review

Abstract

Severe hypertriglyceridemia and familial chylomicronemia syndrome are lipid disorders associated with significant cardiovascular and metabolic risks. The American Congress of Cardiology 2024 highlighted transformative developments in understanding and managing these conditions. Novel therapeutic strategies, particularly targeting genetic and molecular pathways, have emerged, offering hope for improved patient outcomes. This article emphasizes the advancements in pharmacological treatments, diagnostic technologies, and multidisciplinary care approaches. Additionally, the article explores the interplay of genetic, environmental, and secondary factors in hypertriglyceridemia, integrating insights into the clinical differentiation and management of familial chylomicronemia syndrome and multifactorial severe hypertriglyceridemia.